Will a pharma-shaped pin burst the biotech bubble?
This article was originally published in Scrip
This year, a combination of elements has combined to create a meteoric rise in biotech fortunes. But how long will it last? And will H2 see a reversal of riches? Andy Smith explores the inside of the biotech bubble.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.